Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

NCT07227298 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07227298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 30, 2026
Completion date
August 23, 2033
Enrollment
162 (estimated)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic non-small cell lung cancer, carcinoma, non-small cell lung, non-small cell lung cancer